openPR Logo
Press release

Lawsuit filed for Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB)

03-31-2020 10:39 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares over alleged securities laws violations.

A lawsuit was filed on behalf of investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares over alleged securities laws violations.

An investor, who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB), filed a lawsuit over alleged violations of Federal Securities Laws by AnaptysBio, Inc..

Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and for certain investors are short and strict deadlines running. Deadline: May 25, 2020. NASDAQ: ANAB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

San Diego, CA based AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio, Inc's lead drug asset was etokimab (formerly ANB020), a drug intended for the treatment of various inflammatory diseases. in 2018 to $97.33 million in 2019.

On March 26, 2018, an analyst from RBC Capital Markets issued a report that questioned the veracity of data from AnaptysBio's interim analysis of its Phase 2a clinical trial for etokimab in adult patients with peanut allergies that the Company had reported earlier that day. In particular, the RBC report revealed that the response rate for etokimab in the full trial population "does not appear to be meaningfully differentiated" relative to a placebo. Less than five months later, in August 2018, the Company abandoned its clinical pursuit of etokimab as a treatment for peanut allergies.

On June 21, 2019, an analyst from Credit Suisse issued a report questioning the reliability of the Company's Phase 2a atopic dermatitis trial data. Specifically, the Credit Suisse report questioned patients' use of topical corticosteroids to supplement treatment of their symptoms as a rescue therapy during the study and criticized the Company's failure to provide details on the timing of rescue therapy use or whether the subjects that utilized rescue therapy were classified as responders. As a result of the Company's misleading atopic dermatitis trial data, Credit Suisse was "now less certain about etokimab's efficacy profile, particularly in atopic dermatitis."

Then, on November 8, 2019, the Company announced "very disappoint[ing]" data from its ATLAS trial, a Phase 2b multi-dose study which evaluated the efficacy of etokimab in approximately 300 patients with moderate-to-severe atopic dermatitis. Specifically, AnaptysBio disclosed that each of the etokimab dosing arms "failed to meet the primary endpoint of the trial" by not demonstrating statistically greater efficacy relative to a placebo. As a result of these disclosures, the price of AnaptysBio common stock declined precipitously.

The plaintiff claims that between October 10, 2017 and November 7, 2019, the defendants made false and misleading statements regarding the purported efficacy of etokimab, touting data from the Company's Phase 2a trial in peanut allergies as showing a "remarkable efficacy result" and describing the drug as having a "pretty profound efficacy" in its treatment of patients with atopic dermatitis based on AnaptysBio's Phase 2a trial data for that indication, that in truth, the Defendants provided misleading clinical trial data which failed to disclose key information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were, and that as a result of Defendants' misrepresentations, shares of AnaptysBio common stock traded at artificially inflated prices between October 10, 2017 and November 7, 2019.

Those who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) here

News-ID: 1993643 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for AnaptysBio

EGFR Inhibitors-Induced Skin Disorders Market to Observe Stupendous Growth Durin …
The EGFR Inhibitors-Induced Skin Disorders Market is evolving rapidly with the introduction of innovative topical and systemic treatments aimed at managing dermatologic side effects. Pharmaceutical companies are focusing on developing targeted therapies to alleviate symptoms such as rash, itching, and dry skin caused by EGFR inhibitors. Furthermore, advancements in supportive care and skincare regimens are enhancing patient comfort and adherence to treatment, reflecting a growing commitment to addressing the dermatologic
Investigation announced for Investors in AnaptysBio, Inc. (NASDAQ: ANAB) over po …
An investigation on behalf of investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) was announced over potential breaches of fiduciary duties by certain officers and directors at AnaptysBio, Inc. Investors who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain AnaptysBio, Inc. directors breached their fiduciary duties and
AnaptysBio, Inc. (NASDAQ: ANAB) Long Term Investor Alert: Investigation of poten …
An investigation on behalf of current long-term investors in shares of AnaptysBio, Inc. (NASDAQ: ANAB) concerning potential breaches of fiduciary duties by certain directors and officers of AnaptysBio, Inc was announced. Investors who are current long term investors in AnaptysBio, Inc. (NASDAQ: ANAB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on May 25th coming up in Lawsuit filed for Investors in shares of Anapt …
A deadline is coming up on May 25, 2020 in the lawsuit filed for certain investors of AnaptysBio, Inc. (NASDAQ: ANAB) over alleged securities laws violations by AnaptysBio, Inc. Investors who purchased shares of AnaptysBio, Inc. (NASDAQ: ANAB) have certain options and there are strict and short deadlines running. Deadline: May 25, 2020. NASDAQ: ANAB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Antibody Library Technologies Market 2019 By Top Key Players- Dyax, MorphoSys AG …
Antibody libraries are built by leveraging genomic information coding for antibody variable domains that can be procured from naïve donors or B cells of immune. Antibodies are the first proteins which were successfully displayed on the surface of phage by fusing the coding sequence of scFv or Fab to the coat protein. There are various technologies being used for antibody libraries. This has birthed the global antibody library technologies market.
Allergy Therapeutics - Pipeline Analysis 2018 | AnaptysBio, HAL Allergy Group, A …
Allergy is an immune system response, that can range from mild to severe life-threatening reactions. The substances that can cause an allergy are known as allergens. Some common allergens include pollen, dust, insect stings, medications, mold spores, latex, and animal dander. Download the sample report @ https://www.pharmaproff.com/request-sample/1045 Allergy triggers the release of inflammatory mediators such as interleukins, serotonin, cytokines, and prostaglandins, which can produce several systemic physiological reactions like mucous secretion and